We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $588M
1-Year Est. Return 182.75%
This Fund
S&P 500
This Quarter Est. Return
-0.18%
1 Year Est. Return
+182.75%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$383M
AUM Growth
+$150M
Cap. Flow
+$155M
Cap. Flow %
40.41%
Top 10 Hldgs %
48.06%
Holding
163
New
56
Increased
35
Reduced
10
Closed
61

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$20.5M
2
LLY icon
Eli Lilly
LLY
+$16.1M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$9.45M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$7.89M
5
ARGX icon
argenx
ARGX
+$7.32M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$9.05M
2
ABBV icon
AbbVie
ABBV
+$8.88M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$6.68M
4
BPMC
Blueprint Medicines
BPMC
+$5.6M
5
AZN icon
AstraZeneca
AZN
+$3.93M

Sector Composition

Rank Sector Weight
1 Healthcare 32.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRSP icon
26
CALL
CRISPR Therapeutics
CRSP
$4.73B
$3.81M 0.99%
112,000
-78,800
-41% -$3.34M
BMRN icon
27
BioMarin Pharmaceuticals
BMRN
$11.6B
$3.74M 0.98%
+52,877
New +$3.56M
RXRX icon
28
CALL
Recursion Pharmaceuticals
RXRX
$1.59B
$3.69M 0.96%
698,400
+398,400
+133% +$2.9M
ALNY icon
29
Alnylam Pharmaceuticals
ALNY
$27.5B
$3.54M 0.92%
+13,115
New +$3.37M
AGIO icon
30
CALL
Agios Pharmaceuticals
AGIO
$1.79B
$3.51M 0.92%
119,700
+17,700
+17% +$587K
PCVX icon
31
Vaxcyte
PCVX
$7.81B
$3.49M 0.91%
92,385
+82,385
+824% +$6.59M
IMCR icon
32
Immunocore
IMCR
$1.72B
$2.88M 0.75%
+96,984
New +$2.91M
MRNA icon
33
PUT
Moderna
MRNA
$21.8B
$2.83M 0.74%
+100,000
New +$3.55M
RYTM icon
34
Rhythm Pharmaceuticals
RYTM
$6.81B
$2.65M 0.69%
50,000
-25,000
-33% -$1.39M
SWTX
35
DELISTED
SpringWorks Therapeutics
SWTX
$2.65M 0.69%
+60,000
New +$2.76M
MNKD icon
36
CALL
MannKind Corp
MNKD
$1.21B
$2.62M 0.68%
+519,900
New +$2.91M
VKTX icon
37
Viking Therapeutics
VKTX
$3.7B
$2.51M 0.66%
+104,121
New +$3.29M
CNTA
38
DELISTED
Centessa Pharmaceuticals
CNTA
$2.36M 0.62%
164,048
+32,186
+24% +$527K
COGT icon
39
Cogent Biosciences
COGT
$6.65B
$2.35M 0.61%
392,213
+302,213
+336% +$2.37M
VRDN icon
40
Viridian Therapeutics
VRDN
$2.09B
$2.18M 0.57%
162,063
+112,585
+228% +$1.92M
ANAB icon
41
PUT
AnaptysBio
ANAB
$1.58B
$2.18M 0.57%
117,300
+17,300
+17% +$289K
EWTX icon
42
CALL
Edgewise Therapeutics
EWTX
$4.13B
$2.16M 0.56%
+98,200
New +$2.58M
ZYME icon
43
CALL
Zymeworks
ZYME
$1.61B
$2.14M 0.56%
+179,300
New +$2.45M
ALT icon
44
CALL
Altimmune
ALT
$552M
$2.09M 0.55%
418,800
+218,800
+109% +$1.39M
PCVX icon
45
PUT
Vaxcyte
PCVX
$7.81B
$1.95M 0.51%
+51,600
New +$4.13M
SRRK icon
46
Scholar Rock
SRRK
$5.67B
$1.86M 0.49%
57,923
+4,763
+9% +$183K
ANAB icon
47
CALL
AnaptysBio
ANAB
$1.58B
$1.8M 0.47%
96,800
-118,200
-55% -$1.97M
ETNB
48
DELISTED
89bio
ETNB
$1.68M 0.44%
+231,436
New +$2.02M
NVO
49
Novo Nordisk
NVO
$208B
$1.68M 0.44%
+24,618
New +$2.03M
QURE icon
50
CALL
uniQure
QURE
$3.03B
$1.63M 0.43%
154,100
+54,100
+54% +$759K
1
2
3 4 5

Similar funds

MC
Martin & Co Knoxville, Tennessee $587M AUM 16.39% 1-Year Est. Return
PFG
Premier Financial Group Eureka, California $587M AUM 21.88% 1-Year Est. Return
FMI
Frec Markets Inc San Francisco, California $587M AUM
EGWAG
Elwood & Goetz Wealth Advisory Group Athens, Georgia $589M AUM 19.26% 1-Year Est. Return
PFG
PAX Financial Group San Antonio, Texas $586M AUM 15.84% 1-Year Est. Return
GIM
Garden Investment Management Greenwich, Connecticut $586M AUM 15.35% 1-Year Est. Return
FL
Fourthstone LLC St Louis, Missouri $590M AUM 29.58% 1-Year Est. Return
BA
Bellwether Advisors Lincoln, Nebraska $590M AUM 35.66% 1-Year Est. Return

Diadema Partners's Q1 2025 Portfolio in Review

As of Q1 2025, Diadema Partners held 163 positions worth $383M, up 64% from $233M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Diadema Partners deployed $155M of net new capital in Q1 2025, opening 56 new positions and adding to 35 existing holdings. Its largest new stake was Regeneron Pharmaceuticals: 29,828 shares worth $18.9M.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 38% a quarter earlier.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $2.42M trimmed.

  • Diadema Partners's largest Q1 2025 buy was Regeneron Pharmaceuticals: 29,828 shares worth $18.9M.
  • Diadema Partners added most to Jazz Pharmaceuticals in Q1 2025, an estimated $9.45M increase.
  • Diadema Partners's biggest Q1 2025 reduction was Ascendis Pharma A/S, cutting an estimated $2.42M.
  • Diadema Partners fully exited Bristol-Myers Squibb in Q1 2025, selling an estimated $9.05M.
  • Diadema Partners's ten largest holdings make up 48% of its $383M portfolio in Q1 2025.
  • Diadema Partners opened 56 new positions and closed 61 in Q1 2025.
  • Diadema Partners's portfolio value rose 64% quarter-over-quarter to $383M.

Based on Diadema Partners's 13F filing for Q1 2025, filed 15 May 2025.